Stemmatters

Stemmatters is a fully integrated Contract Development and Manufacturing Organization (CDMO) specialising in human cell and tissue products, advanced cell therapies, and complex biologicals.

Founded as a spin-off from the University of Minho, Stemmatters operates from its facilities in Portugal, offering comprehensive solutions for the development and GMP-compliant manufacturing of cell therapies and biological products. The company is committed to advancing the field of regenerative medicine by providing cost-effective and scalable therapeutic solutions.

Key Products and Services:

• Product Development: Expertise in taking therapeutic assets from discovery to market, focusing on cell and tissue-based biologicals.
• Process Development: Engineering robust, scalable, and reproducible manufacturing processes for advanced therapies.
• Analytics: Providing robust and validated product and process analytics essential for quality assurance.
• Cell Therapy Manufacturing: Production of cell-based advanced therapy medicinal products.
• Biopharmaceuticals: Production of biological blood-derived products across all supply chain segments.
• Quality Control: Ensuring patient safety, product performance, and regulatory compliance through stringent quality measures.
• Cell Banking: Maintaining the integrity of cell populations for subsequent applications.
• Aseptic Filling & Storage: Offering semi-automated or manual fill & finish operations in sterile environments.

Stemmatters has developed the mimsys® Platform, a versatile product development platform supporting the formulation of medical devices and investigational medicinal products. This platform is protected by multiple patent families, underscoring the company's commitment to innovation in regenerative medicine.

With a focus on quality and compliance, Stemmatters adheres to EN ISO 9001 and NP 4457 (RDI) Management Systems, ensuring that all processes meet international standards. Through strategic partnerships and a dedicated team, Stemmatters continues to contribute significantly to the advancement of cell therapy and regenerative medicine globally.